ClinicalTrials.gg
RecruitingNCT07324512Updated Nov 19, 2026

Minimum Effective Volume of Crystalloid Co-Loading to Prevent Spinal Anesthesia-Induced Hypotension in Cesarean Section

An interventional study of Intravenous Crystalloid Co-Loading in Spinal Induced Hypotension in Cesarean Delivery, sponsored by Seoul National University Hospital. Recruiting at 1 site in South Korea. Open to female participants aged 19 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Seoul National University Hospital · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.
Updated Nov 19, 2026Now RecruitingFirst site in South Korea+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
45
Allocation
Not applicable
Ages
19 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies in Hypotension by Seoul National University Hospital — 3 open to participants now, 3 under way, none of them phase 3. Hypotension · Seoul National University Hospital.

Planned enrollment
15th of 16
45 · median 94
Started
2026
the only one that year
No phase
13 of 17
2 open now
Registered
17th of 17
by date

Among the 17 studies in Hypotension by Seoul National University Hospital, this one is the 15th largest by planned enrollment of the 16 interventional ones that give a count, is the only one that started in 2026, is one of 13 with no phase, and was the 17th registered.

Hypotension

892 studies on the registry are indexed under Hypotension; 199 are open to participants now.

Browse Hypotension studies →

Open to participants now

3 of the 17 studies in Hypotension by Seoul National University Hospital are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 114 Hypotension studies recruiting now, 53 (46%) set no upper age limit and 36 (32%) stop at 75 or younger; 7 take children under 18; 16 take healthy volunteers.

This study: 19 Years and older · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Hypotension by Seoul National University Hospital, or all of them as a file.
02

Study summary

The goal of this clinical trial is to find the minimum effective volume of IV crystalloid that should be given with phenylephrine to prevent hypotension caused by spinal anesthesia in healthy, term pregnant adults having elective cesarean delivery.

The main questions are:

What is the minimum effective volume (MEV90, mL/kg) of crystalloid co-loading that prevents spinal-anesthesia-induced hypotension in ≥90% of participants?

What maternal side effects and newborn outcomes occur with this strategy (e.g., nausea/vomiting, need for extra vasopressors, total fluids/blood loss, Apgar scores, and umbilical cord blood gases)?

There is no separate comparison group; this is a single-arm, adaptive dose-finding study.

Participants will:

Receive a predefined volume of IV crystalloid over \~10 minutes during spinal anesthesia while phenylephrine is infused. Have blood pressure and symptoms monitored; receive rescue treatment if needed. Allow the next participant's fluid volume to be adjusted based on whether hypotension occurred (biased-coin design). Be followed through postoperative day 2 for maternal and newborn outcomes.

03

Conditions studied

  • Spinal Induced Hypotension in Cesarean Delivery

Browse trials for

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Pregnant adults ≥19 years scheduled for elective cesarean delivery under spinal anesthesia
  • Term pregnancy (≥37 weeks' gestation)

Exclusion criteria

Exclusion Criteria:

  • Emergency cesarean delivery
  • Hypertensive disorders of pregnancy (preeclampsia/eclampsia) or hypertension
  • Multiple gestation
  • Body weight \<50 kg or >35 kg/m²
  • Renal impairment or ≤90 mL/min/1.73 m²
  • Heart failure or other heart disease
  • History of bronchial asthma or other pulmonary disease
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
45 participants (estimated)

Study arms

  • Experimental
    Crystalloid Co-Loading

    Participants undergo spinal anesthesia for elective cesarean delivery. Immediately after intrathecal injection, a predefined volume of balanced crystalloid (co-loading) is infused over \~10 minutes while a prophylactic phenylephrine infusion is initiated per protocol. The crystalloid volume for each successive participant is adjusted using a biased-coin up-and-down algorithm to identify the minimum effective volume that prevents spinal-anesthesia-induced hypotension in ≥90% of patients (MEV90, mL/kg). Blood pressure is monitored frequently; rescue phenylephrine and/or fluids are permitted to maintain predefined blood pressure ranges. Maternal adverse events and neonatal outcomes are recorded through postoperative day 2.

    Other: Intravenous Crystalloid Co-Loading

Interventions

  • OtherIntravenous Crystalloid Co-Loading

    Balanced crystalloid is infused intravenously immediately after intrathecal injection as a co-load. A predefined volume (mL/kg) is administered over \~10 minutes. The volume for successive participants is adapted by a biased-coin up-and-down algorithm to estimate the minimum effective volume (MEV90) that prevents spinal-anesthesia-induced hypotension. Rescue fluids are allowed per protocol.

06

What researchers measure

Primary outcomes

  1. Minimum Effective Volume (MEV90) of Intravenous Crystalloid Co-Loading (mL/kg)

    The smallest crystalloid co-loading dose (mL/kg) that prevents spinal-anesthesia-induced hypotension in ≥90% of participants when given with prophylactic phenylephrine.

    Time frame: From intrathecal injection (start of spinal anesthesia) to end of surgery

Secondary outcomes

  1. Incidence of intraoperative hypotension (mmHg)

    Hypotension is defined as a drop in systolic blood pressure (SBP) to \< 80% of the participant's baseline SBP (mmHg). Baseline SBP is the mean of the last three ward SBP measurements obtained before operating room admission.

    Time frame: From intrathecal injection to end of surgery

  2. Incidence of intraoperative hypertension (mmHg)

    Hypertension is defined as any occurrence of systolic blood pressure (SBP) \> 120% of baseline SBP (mmHg) after spinal anesthesia. Baseline SBP is the mean of the last three ward SBP measurements obtained before operating room admission.

    Time frame: From intrathecal injection to end of surgery

  3. Additional bolus phenylephrine requirement

    Administration of rescue phenylephrine bolus in addition to the protocolized prophylactic phenylephrine infusion to treat or prevent hypotension after spinal anesthesia. Hypotension is defined as SBP \< 80% of baseline SBP (mmHg) or MAP \< 65 mmHg. Baseline SBP is the mean of the last three ward SBP measurements obtained before operating room admission. When hypotension occurs, phenylephrine 100 µg is administered as an IV bolus to restore blood pressure. The outcome is recorded as number of phenylephrine boluses.

    Time frame: From intrathecal injection to end of surgery

  4. Total Phenylephrine Dose (µg)

    Total intraoperative phenylephrine dose administered after spinal anesthesia, defined as the sum of the prophylactic infusion dose and all rescue bolus doses. he prophylactic infusion starts at 1,500 µg/h and the infusion rate is reduced if systolic blood pressure (SBP) exceeds 120% of baseline SBP (mmHg). Baseline SBP is the mean of the last three ward SBP measurements obtained before operating room admission. Rescue bolus protocol: phenylephrine 100 µg IV per hypotensive episode (SBP \< 80% of baseline SBP \[mmHg\] or MAP \< 65 mmHg), repeated as needed. Dose will be abstracted from the anesthesia record (infusion rate × time plus boluses) and summarized in micrograms (µg).

    Time frame: From intrathecal injection to end of surgery

  5. Estimated blood loss (mL)

    Calculated as (suction canister volume - irrigation volume) + gravimetric estimate of soaked sponges/drapes (1 g ≈ 1 mL). For cesarean delivery, amniotic fluid is excluded.

    Time frame: From skin incision to end of surgery

  6. Incidence of Maternal Nausea Associated With Hypotension

    Occurrence of nausea temporally associated with hypotension after spinal anesthesia. Recorded as yes/no (≥1 episode) and number of episodes.

    Time frame: From intrathecal injection to end of surgery

  7. Incidence of Maternal Vomiting Associated With Hypotension

    Occurrence of vomiting temporally associated with hypotension after spinal anesthesia. Recorded as yes/no (≥1 episode) and number of emetic events.

    Time frame: From intrathecal injection to end of surgery

  8. Incidence of Maternal Dizziness/Lightheadedness Associated With Hypotension

    Occurrence of dizziness/lightheadedness temporally associated with hypotension after spinal anesthesia. Recorded as yes/no (≥1 episode) and number of episodes.

    Time frame: From intrathecal injection to end of surgery

  9. Neonatal Apgar score at 1Minute

    The Apgar score (range 0-10) assessed 1 minute after birth by clinical staff according to standard practice. It is the sum (0-2 each) of heart rate, respiratory effort, muscle tone, reflex irritability, and skin color. Recorded as the total score (0-10) and, if available, the five component scores.

    Time frame: At 1 minute after birth

  10. Neonatal Apgar Score at 5 Minutes

    The Apgar score (range 0-10) assessed 5 minutes after birth by clinical staff according to standard practice. It is the sum (0-2 each) of heart rate, respiratory effort, muscle tone, reflex irritability, and skin color. Recorded as the total score (0-10) and, if available, the five component scores.

    Time frame: At 5 minutes after birth

  11. Umbilical Arterial pH

    Umbilical cord arterial blood gas pH obtained immediately after birth from a double-clamped cord segment and analyzed per routine laboratory practice.

    Time frame: At delivery (immediately after birth)

  12. Umbilical Arterial Base Excess (mmol/L)

    Umbilical cord arterial blood gas base excess measured immediately after birth from a double-clamped cord segment, processed per routine laboratory practice.

    Time frame: At delivery (immediately after birth)

  13. Pulmonary edema

    New-onset pulmonary edema within 48 hours after surgery, defined by physician diagnosis supported by clinical findings (e.g., dyspnea, crackles) and/or objective evidence (e.g., new supplemental oxygen requirement or SpO₂ ≤ 92% on room air, chest imaging consistent with interstitial/alveolar edema). Record as yes/no (≥1 event).

    Time frame: Through postoperative day 2

  14. Clinically Significant Generalized Edema

    Generalized pitting edema present within 48 hours after surgery, defined by ≥1 of the following objective criteria (excluding localized, surgical-site-limited edema): (A) Physical exam: pitting grade ≥2+ in ≥2 anatomic regions (e.g., bilateral pretibial/ankle, hands/forearms, sacral, or periorbital), using the standard indentation scale - 2+: \~4 mm pit, brief rebound; 3+: \~6 mm pit, 10-60 s rebound; 4+: \~8 mm pit, \>60 s rebound. (B) Anthropometry: body weight increase ≥2% (or ≥2 kg) from the preoperative baseline or bilateral mid-calf circumference increase ≥2 cm from baseline. (C) Therapeutic criterion: initiation or escalation of diuretic therapy (e.g., IV/PO loop diuretic) for generalized edema as judged by the treating clinician. Recorded as yes/no (≥1 criterion met)

    Time frame: Through postoperative day 2

  15. Acute Heart Failure

    New diagnosis of acute heart failure within 48 hours after surgery, characterized by symptoms/signs (e.g., dyspnea, orthopnea, pulmonary congestion), objective evidence (e.g., chest radiographic congestion, elevated BNP/NT-proBNP if available, or echocardiographic findings), and requirement for treatment (e.g., IV diuretics, vasodilators, inotropes, or noninvasive ventilation). Record as yes/no (≥1 event).

    Time frame: Through postoperative day 2

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for May 2027, 16 months after the start.

Of 213 non-industry interventional studies with no phase under Hypotension, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 23. This study's planned 16 months is above that.

Counting every sponsor, half of 220 studies reached it within 12 months; a quarter within 6 and three quarters within 22.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 19, 2026: start Dec 2025 → Jan 2026, primary completion May 2026 → May 2027 and completion Jun 2026 → Jun 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 14, 2025
First posted
Jan 7, 2026
StartActual
Jan 11, 2026was Dec 2025
Primary completionEst.
May 31, 2027was May 2026
CompletionEst.
Jun 30, 2027was Jun 2026
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 19, 2026
Sites
1 site added — first site in South Korea
Show site
  • Seoul National University Hospital · Seoul, South Korea
Nov 19, 2026
Start date
Dec 27, 2025→Jan 11, 2026 (actual)
Nov 19, 2026
Primary completion
May 31, 2026→May 31, 2027
Nov 19, 2026
Study completion
Jun 30, 2026→Jun 30, 2027
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in South Korea
    Show site
    • Seoul National University Hospital · Seoul, South Korea
    Start date Dec 27, 2025→Jan 11, 2026 (now actual)
    Primary completion May 31, 2026→May 31, 2027
    Study completion Jun 30, 2026→Jun 30, 2027
    + 2 other changes: verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07324512
Responsible party
Sponsor
First posted
Jan 7, 2026
Start date
Jan 11, 2026
Primary completion
May 31, 2027 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Nov 19, 2026

Study contacts

Hansol Kim
Contact
hansolfrkr@gmail.com
+82-02-2072-2467
Hansol Kim
principal investigator · Seoul National University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion